Strong base of technology sector tenants and valuations may provide support
Strong growth in convenience format, margin improvement would support financials
The Covid wave, rising raw material costs can impact near-term sales
Strong growth in convenience format, margin improvement would support financials
Market share gains, margin improvement are other positives for the stock
The stock gains 21 per cent; improvement in financial metrics key to sustain show
While the first three weeks of April saw robust demand in what is considered a seasonally strong period, lockdown in multiple states has seen offtake collapse
Given the near-term sales headwinds, the stock could be under pressure; investors can consider the stock on dips
Given the valuation worries, investors should await further correction before considering the stock
Barring a few names, rally may not sustain in the near term
Tyre companies may not be able to fully pass on the surge in raw material costs
Margin trajectory and valuations to limit upsides
Lack of new launches due to inspection delays, intensifying competition key headwinds
Lower than expected Q4 show, premium valuations were other factors
It should deliver strong revenue growth with relief in the form of easing input costs
Analysts expect ramp-up in biosimilars to be gradual
Margin pressures, valuations too weigh on the stock
Rising exports, price hike, improving mix not enough to offset costs
Stock trading at 74% premium to Hero at valuation of 24.5x its FY23 earnings
While revenue growth was robust in Q4, weak mix, costs dented profits